EGF-receptor tyrosine kinase (TK) inhibitors, such as Gefitinib, are known to reduce lung carcinoma metastasis, but long-term use of Gefitinib leads to drug resistance via MET gene amplification [36] or HGF-dependent pathway [85]. This evidence concerns the gene HGF and lung carcinoma.